Switch theme
Sign up to access all valuation multiples
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
2010
60
Last FY Revenue $25K
Last FY EBITDA -$6.9M
$11.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Pure Biologics achieved revenue of $25K and an EBITDA of -$6.9M.
Pure Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pure Biologics valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $25K | XXX | XXX | XXX |
| Gross Profit | XXX | -$0.7M | XXX | XXX | XXX |
| Gross Margin | XXX | -2709% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -27449% | XXX | XXX | XXX |
| EBIT | XXX | -$7.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -31379% | XXX | XXX | XXX |
| Net Profit | XXX | -$9.5M | XXX | XXX | XXX |
| Net Margin | XXX | -37573% | XXX | XXX | XXX |
| Net Debt | XXX | $2.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pure Biologics's stock price is PLN 7 (or $2).
Pure Biologics has current market cap of PLN 28.6M (or $7.6M), and EV of PLN 42.8M (or $11.4M).
See Pure Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.4M | $7.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pure Biologics has market cap of $7.6M and EV of $11.4M.
Pure Biologics's trades at 450.6x EV/Revenue multiple, and -1.6x EV/EBITDA.
Equity research analysts estimate Pure Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pure Biologics's P/E ratio is not available.
See valuation multiples for Pure Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.6M | XXX | $7.6M | XXX | XXX | XXX |
| EV (current) | $11.4M | XXX | $11.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 450.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPure Biologics's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.1M for the same period.
Pure Biologics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pure Biologics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pure Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27449% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28669% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pure Biologics acquired XXX companies to date.
Last acquisition by Pure Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Pure Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pure Biologics founded? | Pure Biologics was founded in 2010. |
| Where is Pure Biologics headquartered? | Pure Biologics is headquartered in Poland. |
| How many employees does Pure Biologics have? | As of today, Pure Biologics has 60 employees. |
| Is Pure Biologics publicy listed? | Yes, Pure Biologics is a public company listed on WAR. |
| What is the stock symbol of Pure Biologics? | Pure Biologics trades under PUR ticker. |
| When did Pure Biologics go public? | Pure Biologics went public in 2018. |
| Who are competitors of Pure Biologics? | Similar companies to Pure Biologics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pure Biologics? | Pure Biologics's current market cap is $7.6M |
| Is Pure Biologics profitable? | Yes, Pure Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
